INTRODUCTION {#sec1}
============

Pituitary adenomas (PAs) are usually non-malignant monoclonal tumours with an overall prevalence of 16.7% (14.4% in autopsy studies and 22.5% in imaging studies) in the general population ([@ref1]). The majority of PAs, however, are small and nonfunctional tumours, and only 0.16--0.2% of them are macroadenomas ≥10 mm in diameter ([@ref1], [@ref2]). The diagnosis of PAs has improved when MRI scans and hormone analysis in blood serum became more accessible (aggressive biomarkers). The accession of PAs is explained by better detection of microadenomas and the occurring symptoms of macroadenomas ([@ref3]). Clinically, PAs are assorted to nonfunctional pituitary adenomas (NFPA) and functional pituitary adenomas (FPA) ([@ref4]). Compared to FPA, NFPA are more aggressive and complicated to detect because of lack of symptoms that appear only when adenomas enlarge and start to compress surrounding structures ([@ref5]). One of the most important behaviours of PA is invasiveness, which manifests itself by destroying surrounding structures thus triggering a lot of complications ([@ref6]). Also, it has been demonstrated that invasiveness could be a sign of poor prognosis ([@ref6]).

The pathogenesis of PA is complex and poorly understood. It is thought that PA has a multifactorial aetiology; also, genetic factors have an impact on PA development. MMPs have an important role in tumour progression due to the breakdown of their collagen, which is a fundamental structure within the extracellular matrix ([@ref7]--[@ref9]). Degradation of the extracellular matrix gradually increases depending on the level of *MMP-1* ([@ref10]). The matrix metalloproteinase-1 enzyme is important in replacement of collagen fibres in the intercellular matrix ([@ref11]). Rutter et al. ([@ref12]) have announced that the insertion of a G nucleotide at --1607 bp in the nucleotide sequence of the MMP-1 gene promoter generates a new 5′-GGA-3′ sequence that matches the core recognition sequence of the binding site for members of the Ets family of transcription factors ([@ref11], [@ref13]). *MMP-1* levels increased approximately twice compared to normal concentration when this insertion was present, this allowed *MMP-1* to relieve tumour invasion and metastasis ([@ref14]). *MMP-1* is also thought to be significant to tumour development ([@ref11]). Altaş et al. researched the influence of 2G polymorphism on pituitary adenomas and found that 90% of invasive pituitary adenomas manifest in patients who are homozygous for this *MMP-1* SNP ([@ref11]).

The *FGFR4-R388G* SNP is associated with *MMP* expression ([@ref13]). Fibroblast growth factors (FGFs) and their receptors (FGFRs) are a family of ligands and receptors that regulate development, growth, differentiation, migration, and angiogenesis ([@ref1]). It is thought that basic FGF (bFGF; FGF2) is found in bovine pituitary folliculostellate cells responsible for secretion of pituitary hormones ([@ref15]). Deletion of FGF10 or its receptor can be accountable for the disruption of initial pituitary development ([@ref16]). Ezzat et al. ([@ref17]) demonstrated that the amount of FGF mRNA in blood serum correlates with aggressiveness of pituitary tumours.

The aim of our study was to determine if the frequency of the genotypes of *MMP-1* and *FGFR4-R388* had an influence on the development of non-invasive and invasive hypophyseal adenoma.

MATERIALS AND METHODS {#sec2}
=====================

Permission (No. P2-9/2003) to undertake the study was obtained from Kaunas Regional Biomedical Research Ethics Committee. The study was conducted in the departments of ophthalmology and neurosurgery of the Hospital of the Lithuanian University of Health Sciences.

Study participants comprised of 100 subjects with the diagnosis of pituitary adenoma, and the control group involved 200 subjects.

The control group was formed by taking into consideration the distribution of age and gender in the pituitary adenoma group. Therefore, the medians of the patients' age of the control group and the pituitary group did not differ statistically significantly (*p* \< 0.05).

The demographic data of the study subjects are presented in [Table 1](#T1){ref-type="table"}.

The inclusion criteria of the PA group were as follows: 1) established and confirmed PA via MRI; 2) patient's general good condition; 3) patient's consent to take part in the study; 4) age ≥18 years, 5) no other brain or other localized tumours.

Invasiveness evaluation {#sec3}
-----------------------

All pituitary adenomas were analysed based on MRI findings. The suprasellar extension and sphenoid sinus invasion by PAs were classified according to the Wilson Hardy classification (the Hardy classification, modified by Wilson) ([@ref18]). The degree of suprasellar and parasellar extension was graded as stages A--E. The degree of sellar floor erosion was graded as grades I--IV. Grade III, localized sellar destruction, and grade IV, diffused destruction, were considered invasive PA. The Knosp classification system was used to quantify the invasion of the cavernous sinus, in which only grades III and IV define true invasion of the tumour into the cavernous sinus. Grade 0, no cavernous sinus involvement; grades I and II, the tumour pushes into the medial wall of the cavernous sinus, but does not go beyond the hypothetical line extending between the centres of the two segments of the internal carotid artery (grade I) or it goes beyond such a line, but without passing a line tangent to the lateral margins of the artery itself (grade II); grade III, the tumour extends laterally to the internal carotid artery within the cavernous sinus; grade 4, total encasement of the intracavernous carotid artery ([@ref19]). So, grade III and IV tumours were considered to be invasive.

###### 

Demographic characteristics of patients with pituitary adenoma (PA) and the control group subjects

  Characteristic   Group     *p* value    
  ---------------- --------- ------------ ----
  Men, *n* (%)     35 (35)   49 (24.5)    NS
  Women, *n* (%)   65 (65)   151 (75.5)   NS
  Age, median      51.38     49.57        NS

NS -- non-significant

Activeness and recurrence evaluation {#sec4}
------------------------------------

The analysis of all pituitary adenomas was based on histopathological findings of PA and hormone levels in blood serum before surgery. All 100 subjects were categorized into two groups -- active or inactive PA. The active PA group was not broken down into smaller groups by the increase of specific hormone because dominant tumours were prolactinomas and others would not fill the optimal space in our study. Since some of the 100 subjects had already had surgery in recent years, we categorized them by the recurrence of pituitary adenoma into two groups -- with PA and without recurrence.

DNA extraction and genotyping {#sec5}
-----------------------------

The DNA extraction and analysis of the gene polymorphism of *MMP-1* Rs1799750 and *FGFR4-R388* Rs351855 were carried out at the Laboratory of Ophthalmology at the Institute of Neuro-science of the Lithuanian University of Health Sciences. DNA was extracted from 200 μL venous blood (white blood cells) using a DNA purification kit based on the magnetic beads method (Mag-JET Genomic DNA Kit, Thermo Scientific) or the silica-based membrane technology utilizing a genomic DNA extraction kit (GeneJET Genomic DNA Purification Kit, Thermo Scientific), according to the manufacturer's recommendations.

The genotyping of MMP-1Rs1799750 and *FGFR4-R388* Rs351855 was carried out using the real-time PCR method. Both single-nucleotide polymorphisms were determined using TaqMan^®^Drug Metabolism assays (Thermo Scientific).

The genotyping was performed by a Rotor -- Gene Q real-time PCR quantification system (Qiagen, USA), using 2X TaqMan^®^ Universal Master Mix, TaqMan® Drug Metabolism assay, and nuclease-free water. Appropriate real-time PCR mixtures of MMP-1Rs1799750 and *FGFR4-R388* Rs351855 were prepared for determining single-nucleotide polymorphisms.

A PCR reaction mixture (9 μL) was poured into each of the 72 wells of the Rotor-Disc, and then 1 μL of matrix DNA of the samples (\~10 ng) and 1 μL of negative control (--K) were added.

The Allelic Discrimination program was used during the real-time PCR. Then, the assay was continued following the manual provided by the manufacturer ([www.qiagen.com](http://www.qiagen.com), Allelic Discrimination). After that, the Allelic Discrimination program was completed, and the genotyping results were received. The program determined the individual genotypes according to the fluorescence intensity rate of different detectors (VIC and FAM).

Statistical analysis {#sec6}
--------------------

Statistical analysis was performed using the SPSS/W 20.0 software (Statistical Package for the Social Sciences for Windows). The data are presented as absolute numbers with percentages in brackets and average values. The frequencies of genotypes (in percentage) are presented in [Table 2](#T2){ref-type="table"}.

Hardy-Weinberg analysis was performed to compare the observed and expected frequencies of Rs1799750 and Rs351855 using the χ^2^ test in all groups. The distributions of the Rs1799750 and Rs351855 SNPs in the PA and control groups were compared using the χ^2^ test or the Fisher exact test. Binomial logistic regression analysis was performed to estimate the impact of genotypes on PA development. Odds ratios and 95% confidence intervals are presented. The selection of the best genetic model was based on the Akaike Information Criterion (AIC); therefore, the best genetic models were those with the lowest AIC values. Differences were considered statistically significant when *p* \< 0.05.

RESULTS {#sec7}
=======

The frequency of polymorphisms in the *MMP-1* gene (c.-1607 2G) Rs1799750 and *FGFR4-R388* gene (G\>A) Rs351855 was evaluated in both the PA and reference groups ([Table 2](#T2){ref-type="table"}). The distribution of the analyzed *MMP-1* genotypes and allele frequencies in patients with PA did not match and in the control group matched the Hardy-Weinberg equilibrium (*p* \> 0.05). *MMP-1* gene polymorphism analysis in the overall group did not reveal any differences in the genotypes distribution between patients with PA and control group subjects ([Table 2](#T2){ref-type="table"}). The distribution of the analyzed *FGFR4-R388* genotypes and allele frequencies in the control group and in the PA group matched the Hardy-Weinberg equilibrium (*p* \> 0.05). *FGFR4-R388* gene polymorphism analysis in the overall group did not reveal any differences in the genotype distribution between the patients with PA and the control group subjects ([Table 2](#T2){ref-type="table"}).

###### 

The frequency of polymorphisms in the *MMP-1* gene (c.-1607 2G) Rs1799750 and *FGFR4-R388* gene (G\>A) Rs351855 in the PA and reference groups

  Gene             Genotype/ allele   Frequency (%)                                 
  ---------------- ------------------ --------------- ------- ------------- ------- -------
  *MMP-1*          Genotype                                                         
  (c.-1607 2G)     1G/1G              33 (16.5)       0.768   25 (25)       0.022   0.155
  Rs1799750        1G/2G              94 (47)                 38 (38)               
                   2G/2G              73 (36.5)               37 (37)               
                   All                200 (100)               100 (100)             
                   Allele                                                           
                   1G                 160 (40.00)             88 (44.00)            
                   2G                 240 (60.00)             112 (56.00)           
  *FGFR4* (G\>A)   Genotype                                                         
  Rs351855         G/G                95 (47.5)       0.134   45 (45.00)    0.119   0.885
                   G/A                92 (46)                 49 (49.00)            
                   A/A                13 (6.5)                6 (6.00)              
                   All                200 (100)               100 (100)             
                   Allele                                                           
                   G                  282 (70.5)              139 (69.5)            
                   A                  118 (29.5)              61 (30.5)             

PA -- pituitary adenoma, *p* value -- significance level, *p* value-HWE -- significance level by Hardy-Weinberg equilibrium.

Binomial logistic regression analysis in the patients with PA and in the control group was performed ([Table 3](#T3){ref-type="table"}). This analysis revealed that there were no statistically significant variables in the models of the patients with PA and in the control group.

The frequency of the *MMP-1* and *FGFR4* geno-types in the patients with PA and in the control group was evaluated by gender as well. The polymorphism in the *MMP-1* gene was statistically significant in the women's group (*p* \< 0.05). The 1G/2G genotype was significantly less frequent in women in the PA group than in the control group: 30.8% vs. 50.3%, *p* = 0.011. The polymorphism of *FGFR4* was not statistically significant by gender (*p* \> 0.05). The data are presented in [Table 4](#T4){ref-type="table"}.

###### 

Binomial logistic regression analysis in the patients with pituitary adenoma (PA) and in the control group

  Model           Genotype               OR (CI, 95%)           *p* value   AIC
  --------------- ---------------------- ---------------------- ----------- ---------
  *MMP-1*                                                                   
  Codominant      1G2G                   0.798 (0.462; 1.377)   0.417       384.253
  1G1G            1.495 (0.778; 2.872)   0.228                              
  Dominant        1G/2G + 2G/2G          0.979 (0.595; 1.610)   0.932       385.901
  Recessive       1G/1G                  0.593 (0.330; 1.066)   0.081       382.911
  Over-dominant   1G2G                   0.691 (0.423; 1.128)   0.140       383.702
  Additive        \-                     1.162 (0.836; 1.615)   0.370       385.105
  *FGFR4*                                                                   
  Codominant      GA                     1.124 (0.685; 1.846)   0.643       387.665
  AA              0.974 (0.348; 2.730)   0.961                              
  Dominant        G/A+A/A                1.106 (0.683; 1/790)   0.682       385.741
  Recessive       A/A                    1.089 (0.401; 2.956)   0.867       385.880
  Over-dominant   GA                     1.128 (0.697; 1.824)   0.624       385.668
  Additive        \-                     1.056 (0.711; 1.567)   0.788       385.836

###### 

The frequency of the *MMP-1* and *FGFR4* genotypes in the patients with pituitary adenoma (PA) and in the control group, by gender

  *MMP-1* (c.-1607 2G) Rsl799750                                                                                                                                                                      
  -------------------------------- --------------------------------- -------------------------------------- --------------- --------------------------------- --------------------------------------- ---------------
  1G1G (%)                         8 (22.9)                          10 (20.4)                              0.794           17 (26.2)                         23 (15.2)                               0.053
  1G2G (%)                         18 (51.4)                         18 (36.7)                              0.190           20 (30.8)                         76 (50.3)                               0.011
  2G2G (%)                         9 (25.7)                          21 (42.9)                              0.165           28 (43.1)                         52 (34.4)                               0.282
  Allele                                                                                                                                                                                              
  1G                               34 (48.57)                        38 (38.78)                                             54 (41.54)                        122 (40.40)                             
  2G                               36 (51.43)                        60 (61.22)                                             76 (58.46)                        180 (59.60)                             
  ***FGFR4* (G\>A) Rs351855**                                                                                                                                                                         
                                   **PA group *n* (%) (*n* = 35)**   **Control group *n* (%) (*n* = 47)**   ***p* value**   **PA group *n* (%) (*n* = 65)**   **Control group *n* (%) (*n* = 153)**   ***p* value**
  GG (%)                           21 (60.0)                         20 (42.6)                              0.258           24 (36.9)                         75 (49.0)                               0.105
  GA (%)                           12 (34.3)                         23 (48.9)                              0.259           37 (56.9)                         69 (45.1)                               0.138
  AA (%)                           2 (5.7)                           4 (8.5)                                0.697           4 (6.2)                           9 (5.9)                                 1
  Allele                                                                                                                                                                                              
  G                                54 (77.14)                        63 (67.02)                                             85 (65.38)                        219 (71.57)                             
  A                                16 (22.86)                        27 (32.98)                                             45 (34.62)                        87 (28.43)                              

PA -- pituitary adenoma, *p* value -- significance level

Binomial logistic regression analysis was performed by gender. Analysis of the MMP-1 gene in females revealed codominant (*p* = 0.037) and over-dominant (*p* = 0.009) variables were statistically significant, however, in males none of the models showed statistical significance (*p* \> 0.05). Also, there was no statistical significance in the *FGFR4* polymorphism in either of the groups by gender (*p* \> 0.05). The data are presented in [Table 5](#T5){ref-type="table"}.

The frequency of the *MMP-1* and *FGFR4* genotypes in the patients with PA and in the control group by invasiveness of PA was analyzed. Patients with invasive PA had the 1G/2G genotype more frequently than the subjects in the control group: 28.6% vs. 16.5%, *p* = 0.044. However, the 1G/2G genotype was less frequent in the non-invasive PA group than in the control group: 47% vs. 27%, *p* = 0.03. The non-invasive PA group did not match the Hardy-Weinberg equilibrium (HWE) for the MMP-1 gene polymorphism (*p* = 0.02), although the invasive PA and the control group matched HWE for both polymorphisms (*P* \> 0.05). The data are presented in [Table 6](#T6){ref-type="table"}.

###### 

Binomial logistic regression analysis in pituitary adenoma (PA) and the control group by gender

  Model           Genotype               OR (CI, 95%)           *p* value   AIC
  --------------- ---------------------- ---------------------- ----------- ---------
  *MMP-1*                                                                   
  Females                                                                   
  Codominant      1G2G                   0.489 (0.249; 0.958)   0.037       262.394
  1G1G            1.373 (0.631; 2.986)   0.424                              
  Dominant        1G/2A +                0.694 (0.383; 1.258)   0.229       266.792
  1G/1G                                                                     
  Recessive       1G/1G                  0.507 (0.250; 1.031)   0.061       264.804
  Over-dominant   1G2G                   0.439 (0.237; 0.812)   0.009       261.029
  Additive        \-                     1.045 (0.699; 1.562)   0.831       268.186
  Males                                                                     
  Codominant      1G2G                   2.333 (0.843; 6.459)   0.103       117.289
  1G1G            1.867 (0.554; 6.286)   0.314                              
  Dominant        1G/2G +                2.167 (0.841; 5.579)   0.109       115.438
  1G/1G                                                                     
  Recessive       1G1G                   0.865 (0.302; 2.476)   0.787       118.032
  Over-dominant   1G2G                   0.312 (0.076; 1.284)   0.107       51.33
  Additive        \-                     0.312 (0.792; 2.582)   0.236       116.679
  *FGFR4*                                                                   
  Females                                                                   
  Codominant      GA                     1.676 (0.911; 3.081)   0.097       268.847
  AA              1.389 (0.392; 4.918)   0.611                              
  Dominant        G/A+A/A                1.643 (0.906; 2.979)   0.102       268.936
  Recessive       A/A                    0.953 (0.283; 3.213)   0.938       269.650
  Over-dominant   GA                     1.609 (0.896; 2.888)   0.111       267.098
  Additive                               1.408 (0.869; 2.281)   0.165       267.722
  Males                                                                     
  Codominant      GA                     0.497 (0.196; 1.258)   0.140       115.456
  AA              0.476 (0.078; 2.894)   0.420                              
  Dominant        G/A+A/A                0.494 (0.203; 1.202)   0.120       113.458
  Recessive       A/A                    1.535 (0.265; 8.894)   0.633       115.677
  Over-dominant   GA                     0.544 (0.221; 1.342)   0.187       114.138
  Additive        \-                     0.585 (0.281; 1.217)   0.151       113.767

###### 

The frequency of the *MMP-1* and *FGFR4* genotypes in the patients with pituitary adenoma (PA) and in the control group by the invasiveness of PA

  Gene                             Genotype/allele                            Frequency (%)                                                                                                           
  -------------------------------- ------------------------------------------ --------------- -------------------------------------------- ------- ------------------------------------------ ------- --
  *MMP-1* (c.-1607 2G) Rsl799750   Genotype                                                                                                                                                           
  1G/1G                            33[\*](#TF1){ref-type="table-fn"} (16.5)   0.768           7 (18.9)                                     0.020   18[\*](#TF1){ref-type="table-fn"} (28.6)   0.379   
  1G/2G                            94[\*\*](#TF2){ref-type="table-fn"} (47)                   10[\*\*](#TF2){ref-type="table-fn"} (27.0)           28 (44.4)                                          
  2G/2G                            73 (36.5)                                                  20 (54.1)                                            17 (27)                                            
  All                              200 (100)                                                  37 (100)                                             63 (100)                                           
  Allele                                                                                                                                                                                              
  1G                               160 (40.00)                                                24 (32.43)                                           64 (50.79)                                         
  2G                               240 (60.00)                                                50 (67.57)                                           62 (49.21)                                         
  *FGFR4* (G\>A) Rs351855          Genotype                                                                                                                                                           
  G/G                              95 (47.5)                                  0.134           17 (45.9)                                    0.659   28 (44.4)                                  0.102   
  G/A                              92 (46)                                                    17 (45.9)                                            32 (50.8)                                          
  A/A                              13 (6.5)                                                   3 (8.1)                                              3 (4.8)                                            
  All                              200 (100)                                                  37 (100)                                             63 (100)                                           
  Allele                                                                                                                                                                                              
  G                                282 (70.5)                                                 51 (68.92)                                           88 (69.84)                                         
  A                                118 (29.5)                                                 23 (31.08)                                           38 (30.16)                                         

PA -- pituitary adenoma, *p* value -- significance level

\* *p* = 0.044

\*\* *p* = 0.030

Binomial logistic regression analysis in the invasive PA group for the *MMP-1* gene polymorphism revealed that the dominant variable (*p* = 0.037) was statistically significant. There was no statistical significance in the *FGFR4* polymorphism in both groups by the invasiveness of PA (*p* \> 0.05). The data are presented in [Table 7](#T7){ref-type="table"}.

We analyzed the frequency of the *MMP-1* and *FGFR4* genotypes in the patients with PA and in the control group by the activity of PA. The 1G/1G genotype was more frequent in the active PA group than in the control group: 28.4% vs. 16.5%, *p* = 0.049. The active PA group did not match the Hardy-Weinberg equilibrium for polymorphism in the *MMP-1* gene (*p* = 0.04), although all other groups matched the HWE by genotype distributions (*p* \> 0.05). The data are presented in [Table 8](#T8){ref-type="table"}.

###### 

Binomial logistic regression analysis in the PA group and the control group by the invasiveness of PA

  Model             Genotype               OR (95% CI)            *p*value   AIC
  ----------------- ---------------------- ---------------------- ---------- ---------
  *MMP-1*                                                                    
  Non-invasive PA                                                            
  Codominant        1G2G                   0.502 (0.177; 1.425)   0.195      207.767
  1G1G              1.292 (0.498; 3.353)   0.599                             
  Dominant          1G/2G + 1G/1G          0.489 (0.241; 2.992)   0.047      205.381
  Recessive         1G/1G                  1.181 (0.478; 2.914)   0.718      209.199
  Over-dominant     1G2G                   0.418 (0.192; 2.908)   0.028      204.051
  Additive          \-                     1.069 (0.998; 1.145)   0.057      205.705
  Invasive PA                                                                
  Codominant        1G2G                   0.546 (0.268; 1.114)   0.096      290.891
  2G2G              0.427 (0.196; 0.931)   0.032                             
  Dominant          1G/2G + 2G/2G          0.494 (0.255; 0.958)   0.037      289.406
  Recessive         2G/2G                  0.634 (0.344; 1.203)   0.167      291.610
  Over-dominant     1G2G                   0.902 (0.511; 1.594)   0.723      293.465
  Additive          \_                     0.658 (0.442; 0.978)   0.039      289.267
  FGFR4                                                                      
  Non-invasive PA                                                            
  Codominant        GA                     0.801 (0.206; 3.113)   0.748      211.196
  AA                0.775 (0.200; 3.013)   0.713                             
  Dominant          G/A+A/A                0.788 (0.213; 2.913)   0.721      209.203
  Recessive         A/A                    0.939 (0.465; 1.899)   0.862      209.295
  Over-dominant     GA                     0.998 (0.494; 2.017)   0.995      209.326
  Additive          ~-~                    0.920 (0.522; 1.622)   0.773      209.243
  Invasive PA                                                                
  Codominant        GA                     1.507 (0.403; 5.632)   0.542      295.013
  AA                1.277 (0.340; 4.801)   0.717                             
  Dominant          G/A+A/A                1.390 (0.383; 5.044)   0.616      293.324
  Recessive         A/A                    0.884 (0.500; 1.562)   0.672      293.411
  Over-dominant     GA                     1.212 (0.687; 2.136)   0.507      293.150
  Additive          \-                     0.964 (0.604; 1.541)   0.880      293.568

###### 

The frequency of the *MMP-1* and *FGFR4* genotypes in the patients with pituitary adenoma (PA) and in the control group by the activity of PA

  Gene                Genotype/allele                            Frequency (%)                                                                           
  ------------------- ------------------------------------------ --------------- ------------ ------- ------------------------------------------ ------- --
  *MMP-1* Rs1799750   Genotype                                                                                                                           
  1G/1G               33[\*](#TF3){ref-type="table-fn"} (16.5)   0.768           6 (18.2)     0.349   19[\*](#TF3){ref-type="table-fn"} (28.4)   0.040   
  1G/2G               94 (47)                                                    13 (39.4)            25 (37.3)                                          
  2G/2G               73 (36.5)                                                  14 (42.4)            23 (34.3)                                          
  All                 200 (100)                                                  33 (100)             67 (100)                                           
  Allele                                                                                                                                                 
  1G                  160 (40.00)                                                25 (37.88)           63 (47.01)                                         
  2G                  240 (60.00)                                                41 (62.12)           71 (52.99)                                         
  *FGFR4* Rs351855    Genotype                                                                                                                           
  G/G                 95 (47.5)                                  0.134           14 (42.4)    0.094   31 (46.3)                                  0.464   
  G/A                 92 (46)                                                    18 (54.5)            31 (46.3)                                          
  A/A                 13 (6.5)                                                   1 (3.0)              5 (7.5)                                            
  All                 200 (100)                                                  33 (100)             67 (100)                                           
  Allele                                                                                                                                                 
  G                   282 (70.5)                                                 46 (69.7)            93 (69.4)                                          
  A                   118 (29.5)                                                 20 (30.3)            41 (30.6)                                          

PA -- pituitary adenoma, *p* value -- significance level

\* *p* = 0.049

Binomial logistic regression analysis in the active PA group for *MMP-1* revealed that the codominant (*p* = 0.035) and dominant (*p* = 0.036) variables were statistically significant, but in the inactive PA group no statistical significance (*p* \> 0.05) was found. There was no statistical significance in the *FGFR4* polymorphism in both groups by the activity of PA (*p* \> 0.05) as well. The data are presented in [Table 9](#T9){ref-type="table"}.

The frequency of the *MMP-1* and *FGFR4* genotypes in the patients with PA and in the con-trol group by the recurrence of PA were investigated. The 1G/1G genotype was more frequent in the PA without recurrence group than in the control group: 27.7% vs. 16.5%, *p* = 0.034. The PA without recurrence group did not match the HWE (*p* = 0.013), although the PA group with recurrence and control groups matched (*p* \> 0.05). All groups matched the HWE for genotype distributions of FGFR4 (*p* \> 0.05) ([Table 10](#T10){ref-type="table"}).

Binomial logistic regression analysis in PA without recurrence group for *MMP-1* revealed that the recessive (*p* = 0.033) variable was statistically significant. There was no statistical significance of variables in analysis of *FGFR4* in either of the groups by the recurrence of PA (*p* \> 0.05). The data are presented in [Table 11](#T11){ref-type="table"}.

###### 

Binomial logistic regression analysis in the PA group and the control group by the activity of PA

  Model           Genotype                OR (95% CI)             *p* value   AIC
  --------------- ----------------------- ----------------------- ----------- ---------
  *MMP-1*                                                                     
  Inactive PA                                                                 
  Codominant      1G2G                    0.721 (0.319; 1.628)    0.431       195.412
  2G2G            0.948 (0.335; 2.685)    0.920                               
  Dominant        1G/2G + 1G/1G           0.780 (0.369; 1.648)    0.515       193.668
  Recessive       1G/1G                   1.125 (0.431; 2.938)    0.811       194.031
  Over-dominant   1G2G                    0.733 (0.346; 1.554)    0.418       193.422
  Additive        \-                      0.918 (0.543; 1.553)    0.749       193.985
  Active PA                                                                   
  Codominant      1G2G                    0.462 (0.226; 0.946)    0.035       301.334
  2G2G            0.547 (0.263; 1.140)    0.107                               
  Dominant        1G/2G + 1G/1G           0.499 (0.261; 0.956)    0.036       300.600
  Recessive       1G/1G                   0.909 (0.509; 1.625)    0.749       304.732
  Over-dominant   1G2G                    0.671 (0.380; 1.184)    0.169       302.910
  Additive        \-                      0.768 (0.525; 1.122)    0.172       302.971
  *FGFR4*                                                                     
  Inactive PA                                                                 
  Codominant      GA                      2.543 (0.313; 20.682)   0.383       194.832
  AA              1.916 (0.232; 15.801)   0.546                               
  Dominant        G/A + A/A               2.225 (0.281; 17.598)   0.449       193.377
  Recessive       A/A                     0.814 (0.387; 1.714)    0.589       193.793
  Over-dominant   GA                      1.409 (0.672; 2.951)    0.364       193.259
  Additive        \-                      0.957 (0.520; 1.760)    0.887       194.067
  Active PA                                                                   
  Codominant      GA                      0.876 (0.289; 2.655)    0.815       306.751
  AA              0.848 (0.280; 2.570)    0.771                               
  Dominant        G/A + A/A               0.862 (0.295; 2.515)    0.786       304.763
  Recessive       A/A                     0.952 (0.547; 1.657)    0.861       304.804
  Over-dominant   GA                      1.011 (0.580; 1.761)    0.970       304.834
  Additive        \-                      0.944 (0.602; 1.479)    0.800       304.771

###### 

The frequency of the *MMP-1* and *FGFR4* genotypes in the patients with the PA group and in the control group by the recurrence of PA

  Gene                Genotype/allele                            Frequency(%)                                                                           
  ------------------- ------------------------------------------ -------------- ------------------------------------------ ------- ------------ ------- --
  *MMP-1* Rs1799750   Genotype                                                                                                                          
  1G/1G               33[\*](#TF4){ref-type="table-fn"} (16.5)   0.768          23[\*](#TF4){ref-type="table-fn"} (27.7)   0.013   2 (11.8)     0.900   
  1G/2G               94 (47)                                                   30 (36.1)                                          8 (47.1)             
  2G/2G               73 (36.5)                                                 30 (36.1)                                          7 (41.2)             
  All                 200 (100)                                                 83 (100)                                           17 (100)             
  Allele                                                                                                                                                
  1G                  160 (40.00)                                               76 (45.78)                                         12 (35.29)           
  2G                  240 (60.00)                                               90 (54.22)                                         22 (64.71)           
  *FGFR4* Rs351855    Genotype                                                                                                                          
  G/G                 95 (47.5)                                  0.134          39 (47.0)                                  0.239   6 (35.3)     0.235   
  G/A                 92 (46)                                                   39 (47.0)                                          10 (58.8)            
  A/A                 13 (6.5)                                                  5 (6.0)                                            1 (5.9)              
  All                 200 (100)                                                 83 (100)                                           17 (100)             
  Allele                                                                                                                                                
  G                   282 (70.50)                                               117 (70.48)                                        22 (64.71)           
  A                   118 (29.50)                                               49 (29.52)                                         12 (35.29)           

PA -- pituitary adenoma, *p* value -- significance level

\* *p* = 0.034

###### 

Binomial logistic regression analysis in the PA group and the control group by the recurrence of PA

  Model                   Genotype               OR (95% CI)             *p* value   AIC
  ----------------------- ---------------------- ----------------------- ----------- ---------
  *MMP-1*                                                                            
  PA without recurrence                                                              
  Codominant              1G2G                   0.777 (0.430; 1.403)    0.02        343.331
  2G2G                    1.696 (0.858; 3.352)   0.129                               
  Dominant                1G/2G + 1G/1G          1.015 (0.596; 1.729)    0.955       346.465
  Recessive               1G/1G                  1.940 (1.055; 3.565)    0.033       342.033
  Over-dominant           1G2G                   0.638 (0.377; 1.081)    0.095       343.630
  Additive                \-                     1.240 (0.875; 1.759)    0.226       345.005
                                                 PA with recurrence                  
  Codominant              1G2G                   0.888 (0.308; 2.560)    0.825       124.891
  2G2G                    0.632 (0.125; 3.208)   0.580                               
  Dominant                1G/2G + 1G1G           0.821 (0.300; 2.250)    0.702       123.074
  Recessive               1G/1G                  0.675 (0.147; 3.091)    0.612       124.939
  Over-dominant           1G2G                   1.002 (0.372; 2.703)    0.996       123.219
  Additive                \-                     0.821 (0.397; 1.696)    0.594       122.930
  *FGFR4*                                                                            
                                                 PA without recurrence               
  Codominant              GA                     1.102 (0.368; 3.302)    0.862       348.432
  AA                      1.067 (0.356; 3.196)   0.907                               
  Dominant                G/A+A/A                1.084 (0.374; 3.145)    0.881       346.446
  Recessive               A/A                    0.980 (0.587; 1.636)    0.937       346.462
  Over-dominant           GA                     1.041 (0.623; 1.738)    0.879       346.445
  Additive                \-                     0.999 (0.656; 1.522)    0.996       346.468
                                                 PA with recurrence                  
  Codominant              GA                     1.413 (0.167; 11.963)   0.751       124.155
  AA                      0.821 (0.091; 7.372)   0.860                               
  Dominant                G/A+A/A                1.112 (0.137; 9.056)    0.921       123.209
  Recessive               A/A                    0.603 (0.215; 1.693)    0.337       122.264
  Over-dominant           GA                     1.677 (0.614; 4.582)    0.313       122.185
  Additive                ~-~                    0.738 (0.334; 1.629)    0.452       122.662

DISCUSSION {#sec8}
==========

Our results revealed that the *MMP-1* gene 1G/1G genotype was more frequent in the invasive PA group than in the control group: 28.6% vs. 16.5%, *p* = 0.044, and the 1G/2G genotype was less frequent in non-invasive PA compared to the control group: 27% vs. 47%, *p* = 0.030. To our knowledge, there has been only one study by Altaş M. et al. ([@ref11]) analyzing *MMP-1* gene polymorphism on the development of pituitary adenoma. Scientists in this research revealed that the prevalence of the *MMP-1* gene was: 36.6% had the 2G/2G genotype, 46.6% had the 1G/2G genotype, and 16.6% had the 1G/1G genotype. The 2G allele frequency was found to be 83.4%. In 90% of cases of invasive adenoma, a homozygous 2G/2G genotype was detected ([@ref11]). So we are in disagreement with the study done by Altaş et al. who did not find the same association as we did ([@ref11]). To our knowledge, the study of Altaş et al., did not evaluate either the association between PA hormonal activity or the association with gender. Our results revealed that the 1G/2G genotype was more frequent in women in the control group than in the PA group: 50.3% vs. 30.8%, *p* = 0.011, and the polymorphism in the *MMP-1* gene 1G/1G genotype was more frequent in the active PA group than in the control group: 28.4% vs. 16.5%, *p* = 0.044. Monsalves et al. found that *MMP-1* immunoreactivity was observed in 93% of PAs ([@ref20]).

Other researchers state that *MMP-1* expression is associated with a poor outcome in such cancers as oral carcinoma ([@ref21], [@ref22]), nasopharyngeal carcinoma ([@ref23]), colorectal cancer (CRC) ([@ref24]), gastric cancer ([@ref25]), and pancreatic cancer ([@ref26]); the relevance of *MMP-1* in both CRC and esophageal cancer has been reported by Murray et al. ([@ref27], [@ref28]). Also, a few studies have shown that an elevated expression of *MMP-1* can promote local growth and formation of brain metastases by breast cancer cells ([@ref29], [@ref30]). Other studies have revealed that SLFN5 (human schlafen 5) increases *MMP-1* and *MMP-13* which promote malignant cell motility in renal cell carcinoma ([@ref31]), although in meningiomas *MMP-1* did not have an effect on initiation, growth, or progression ([@ref32]). Monsalves et al. state that the high *FGFR4* levels of PAs seem to be responsible for the induction of *MMP-1* expression in PAs. A similar correlation has been observed with the *FGFR4* expression levels and *MMP-1* score of pituitary tumour groups ([@ref20]).

It was discovered that the other gene investigated in our study, *FGFR4-R388*, did not play any predominant role in PA development. It is thought that ptd-*FGFR4* expression can provoke invasive growth of pituitary tumour cells *in vivo* because of deprivation of membranous N-cadherin ([@ref1], [@ref33], [@ref34]). The FGF family has been described as having an impact on pituitary tumour activeness, aggressiveness, and invasiveness ([@ref11], [@ref13], [@ref15]). A total of 23 FGF ligands have been identified. FGF signals are transduced through FGF receptors with specific affinity for selected receptor isoforms. Although the *FGFR4* was found to be an aggressive pituitary tumour marker ([@ref35]--[@ref37]), we did not discover any linkage between FGFR SNP and hypophyseal tumour development, invasiveness, and activeness, and we are in disagreement with these studies. Other researchers state that *FGFR4-R388* single nucleotide polymorphism is found in up to 50% of the population and has an impact on advanced or treatment-resistant prostate carcinoma, head and neck carcinomas, breast carcinoma, sarcomas, and colorectal carcinoma ([@ref38]--[@ref41]).

At this moment there are an insufficient number of studies in the literature that have investigated the polymorphism of the *MMP-1* and *FGFR4-G388* genes promoter region in brain tumours, especially in PA. Therefore additional studies should address the progression and invasiveness of PA. The effect of the *MMP-1* and *FGFR4-G388* promoter polymorphisms will become clearer through these types of studies and such studies will help us understand the relationship between polymorphisms of these genes and progression and invasiveness of the PA tumour.

CONCLUSIONS {#sec9}
===========

The Rs1799750 polymorphism 1G/1G in the *MMP-1* gene may play a role in invasive and active PA development. This discovery contradicts with the study by Altaş M. et al. who did not find the same association as we did. It is important to research the effect of *MMP-1* in brain tumours to find out the link between this polymorphism and the progression, recurrence, activeness, and invasiveness of PA.
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